Robert A. Nagourney, MD, is Medical and Laboratory Director at Rational Therapeutics, Inc., in Long Beach, California, and an instructor of
Pharmacology at the University of California, Irvine School of Medicine. He
is board certified in internal medicine, medical oncology, and hematology.
A native of Bridgeport, Connecticut, Dr. Nagourney completed undergraduate
education at Boston University, earning a BA in Chemistry, Summa Cum Laude,
Phi Beta Kappa with Distinction in Biochemistry. He received his MD at
McGill University in Montreal, Canada, where he was a University Scholar.
After completing his residency in Internal Medicine at the University of
California, Irvine, Dr. Nagourney received fellowship training in Medical
Oncology at Georgetown University in Washington, DC. He went on to complete
a second fellowship in hematology at the Scripps Institute in La Jolla,
California, where he was the recipient of the Scripps Institute Young
Investigator Award.
Dr. Nagourney went on to found Rational Therapeutics, a cancer research
institute located in Long Beach, California, that has pioneered the
development of “functional profiling” in human tumors. The functional
profiling platform uses human tumor microspheroids in primary culture to
measure drug induced programmed cell death, both apoptotic and
non-apoptotic. It has proven a robust method for the prediction of clinical
response to therapy. Following its successful application to cytotoxic drugs
and radiation, this platform has now been successfully applied in the
development of novel compounds, drug combinations and to the study of signal
transduction inhibitors and “targeted” agents.
With over 20 years experience in human tumor primary culture analyses, Dr.
Nagourney has authored more than 100 manuscripts, book chapters and
abstracts including publications in the Journal of Clinical Oncology,
Gynecological Oncology and The Journal of National Cancer Institute. As
co-investigator on national cooperative trials, Dr. Nagourney is recognized
for the introduction of Platin/Gemcitabine doublets to the treatment of
advanced ovarian and breast cancer. A frequently invited lecturer for
numerous professional organizations and universities, Dr. Nagourney has
served as a reviewer and on the editorial boards of several journals
including Clinical Cancer Research, British Journal of Cancer, Gynecologic
Oncology, Cancer Research and the Journal of Medicinal Food. Dr Nagourney
resides in Long Beach, California with his wife and two sons.
Fore More Information Please Visit:
Today's Honoree is The #1 Blog For Recognizing The Works of Others 